Literature DB >> 25732034

Prevention of hepatitis B.

Mei-Hwei Chang1, Ding-Shinn Chen2.   

Abstract

Hepatitis B virus (HBV) causes life-threatening liver disease. It is transmitted through a horizontal route or a mother-to-infant route, and the latter is the major route in endemic areas. Prevention of HBV infection by immunization is the best way to eliminate HBV-related diseases. The HBV vaccine is the first human vaccine using a viral antigen from infected persons, which is safe and effective. Either passive immunization by hepatitis B immunoglobulin (HBIG) or active immunization by HBV vaccine is effective, and a combination of both yields the best efficacy in preventing HBV infection. The impact of universal HBV immunization is huge, with 90%-95% effectiveness in preventing chronic HBV infection. It is the first cancer preventive vaccine with a protective efficacy against hepatocellular carcinoma (HCC) of ∼ 70%. Nevertheless, further effort is still needed to avoid vaccine failure and to increase the global coverage rate.
Copyright © 2015 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25732034      PMCID: PMC4355249          DOI: 10.1101/cshperspect.a021493

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  64 in total

1.  Universal hepatitis B vaccination: killing 2 birds with 1 stone.

Authors:  Jia-Horng Kao; Ding-Shinn Chen
Journal:  Am J Med       Date:  2008-12       Impact factor: 4.965

Review 2.  Cancer prevention in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013.

Authors:  Arb-Aroon Lertkhachonsuk; Cheng Har Yip; Thiravud Khuhaprema; Ding-Shinn Chen; Martyn Plummer; Sun Ha Jee; Masakazu Toi; Sarikapan Wilailak
Journal:  Lancet Oncol       Date:  2013-11       Impact factor: 41.316

3.  Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program.

Authors:  Brian J McMahon; Lisa R Bulkow; Rosalyn J Singleton; James Williams; Mary Snowball; Chriss Homan; Alan J Parkinson
Journal:  Hepatology       Date:  2011-07-19       Impact factor: 17.425

4.  Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal).

Authors:  P Maupas; J P Chiron; F Barin; P Coursaget; A Goudeau; J Perrin; F Denis; I D Mar
Journal:  Lancet       Date:  1981-02-07       Impact factor: 79.321

5.  Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program.

Authors:  Khunton Wichajarn; Pope Kosalaraksa; Surapon Wiangnon
Journal:  Asian Pac J Cancer Prev       Date:  2008 Jul-Sep

6.  Vaccine against human hepatitis B.

Authors:  E B Buynak; R R Roehm; A A Tytell; A U Bertland; G P Lampson; M R Hilleman
Journal:  JAMA       Date:  1976-06-28       Impact factor: 56.272

7.  Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention.

Authors:  Wan-Hsin Wen; Mei-Hwei Chang; Lu-Lu Zhao; Yen-Hsuan Ni; Hong-Yuan Hsu; Jia-Feng Wu; Pei-Jer Chen; Ding-Shinn Chen; Huey-Ling Chen
Journal:  J Hepatol       Date:  2013-02-26       Impact factor: 25.083

Review 8.  Rocks along the road to the control of HBV and HCC.

Authors:  R Palmer Beasley
Journal:  Ann Epidemiol       Date:  2009-04       Impact factor: 3.797

9.  Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection.

Authors:  M van Zonneveld; A B van Nunen; H G M Niesters; R A de Man; S W Schalm; H L A Janssen
Journal:  J Viral Hepat       Date:  2003-07       Impact factor: 3.728

10.  Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986-90) and in the nationwide immunisation program.

Authors:  Thomas J Peto; Maimuma E Mendy; Yamundow Lowe; Emily L Webb; Hilton C Whittle; Andrew J Hall
Journal:  BMC Infect Dis       Date:  2014-01-07       Impact factor: 3.090

View more
  8 in total

1.  Knowledge, awareness, attitude, and practice of health-care professionals toward hepatitis B disease and vaccination in Saudi Arabia.

Authors:  Thamir M Alshammari; Mohamad Aljofan; Gehad Subaie; Talib Hussain
Journal:  Hum Vaccin Immunother       Date:  2019-09-03       Impact factor: 3.452

Review 2.  Approved Antiviral Drugs over the Past 50 Years.

Authors:  Erik De Clercq; Guangdi Li
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

3.  Detection and Prevention of Virus Infection.

Authors:  Ying Wang; Bairong Shen
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 4.  Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma.

Authors:  Caecilia H C Sukowati; Korri E El-Khobar; Susan I Ie; Beatrice Anfuso; David H Muljono; Claudio Tiribelli
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

5.  Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients.

Authors:  Tyng-Yuan Jang; Pei-Chin Lin; Ching-I Huang; Yu-Mei Liao; Ming-Lun Yeh; Yu-Sheng Zeng; Po-Cheng Liang; Wan-Yi Hsu; Shih-Pien Tsai; Zu-Yau Lin; Shinn-Cherng Chen; Jee-Fu Huang; Chia-Yen Dai; Chung-Feng Huang; Shyh-Shin Chiou; Wan-Long Chuang; Ming-Lung Yu
Journal:  PLoS One       Date:  2017-06-09       Impact factor: 3.240

Review 6.  Immunizations in Athletes.

Authors:  Christopher D Boston; Jennifer J Bryan
Journal:  Sports Health       Date:  2018-07-30       Impact factor: 3.843

7.  Assessment of Hepatitis B Vaccination Status and Associated Factors among Healthcare Workers in Bosaso, Puntland, Somalia 2020.

Authors:  Nur Ahmed Hussein; Abdiwahid Mohamed Ismail; Saaid Said Jama
Journal:  Biomed Res Int       Date:  2022-03-21       Impact factor: 3.411

8.  "Titer of anti-HBs in health professions trainees: prevalence of antibody coverage in a University of Central Italy".

Authors:  Luca Di Giampaolo; Erica Costantini; Marta Di Nicola; Annamaria Porreca; Gioele D'Amore; Luca Coppeta; Rocco Mangifesta
Journal:  Hum Vaccin Immunother       Date:  2021-06-24       Impact factor: 3.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.